Biomarker ID | 378 |
PMID | 18948370 |
Year | 2008 |
Biomarker | Methylation Status of RASSF1 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Expressed Prostatic Secretion |
Subjects | Humans |
Regulation | Hypermethylated in Prostate Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | OR = 1.354 (95% CI: 0.813- 2.464) |
Effect on Pathways | Pathways Include:-Bladder cancer,Non-small cell lung cancer,p53 activity regulation,Pathways in cancer |
Experiment | Benign vs. PCA |
Type of Biomarker | Diagnostic |
Cohort | Of the 74 specimen cohort, only the 63 that yielded >300 ng total nucleic acid were used for DNA methylation analysis.Out of which 33 had Benign tumors and 30 had PCA. |
Senstivity | NA |
Specificity | NA |
AUC | 0.641 (95% CI: 0.504- 0.777) |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | methylation-sensitive TaqMan QPCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | RASSF1 |